Cognition Therapeutics
CGTX
37 hedge funds and large institutions have $13.3M invested in Cognition Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
27% more capital invested
Capital invested by funds: $10.4M → $13.3M (+$2.86M)
3% more funds holding
Funds holding: 36 → 37 (+1)
0.28% less ownership
Funds ownership: 23.87% → 23.59% (-0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mercer Global Advisors
Denver,
Colorado
|
+$152K |
| 2 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$73.3K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$53.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.8K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$37.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWM
Perigon Wealth Management
San Francisco,
California
|
-$322K |
| 2 |
VC
Voss Capital
Houston,
Texas
|
-$86.7K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$68.8K |
| 4 |
NCM
Neumann Capital Management
Foster City,
California
|
-$48.1K |
| 5 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$14.7K |
CGTX Hedge Fund Activity: Q4 2023 in Review
37 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q4 2023, worth a combined $13.3M — up 27% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CGTX positions and 4 closed out — a net gain of 3 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Mercer Global Advisors, adding an estimated $152K. The largest seller was Perigon Wealth Management, exiting entirely with an estimated $322K sold.
- 37 institutional investors held Cognition Therapeutics (CGTX) as of Q4 2023, up from 36 in Q3 2023.
- Funds reported $13.3M of Cognition Therapeutics stock for Q4 2023, up 27% quarter-over-quarter.
- 7 funds opened new Cognition Therapeutics positions in Q4 2023 and 4 closed out, a net change of +3 holders.
- The largest Cognition Therapeutics buyer in Q4 2023 was Mercer Global Advisors, an estimated $152K added.
- The largest Cognition Therapeutics seller in Q4 2023 was Perigon Wealth Management, an estimated $322K sold.
Based on aggregated 13F filings for Q4 2023.